Pharmacogenetics and antiepileptic drugs

Epilepsia

Volumn 42, Issue SUPPL. 5, 2001, Pages 31-34

  Spear, Brian B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Association study; Drug metabolism; Epilepsy genetics; Gene polymorphism

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; PHENYTOIN;

CONFERENCE PAPER; DNA SEQUENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TECHNOLOGY;

EID: 0034785484     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2001.0s006.x     Document Type: Conference Paper

References (21)

1. Recent advances in the genetics of epilepsy: Insights from human and animal studies
2. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
3. Role of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
4. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
5. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
6. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
7. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
8. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
9. Biochemistry and molecular biology of the human CYP2C subfamily
10. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism
11. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
12. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine
13. Pharmacogenetic association between ALOX5 promoter genotype and the response to antiasthma treatment
14. 2-adrenergic receptor in normal and asthmatic subjects
15. 2-adrenergic receptors and asthma
16. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing
17. 2-adrenergic receptor in the response to regular use of albuterol in asthma
18. The pharmacogenetics of codeine hypoalgesia
19. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms
20. Variations on a theme: Cataloging human DNA sequence variation